In intensified bioprocessing, the engineered CHO host supports higher titers and long culture duration in continuous perfusion.

With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.

Over the past decade, however, a wave of technological advances has begun to expand the druggable proteome. These include covalent inhibitors (such as sotorasib), chemical proteomics, and AI-enabled ...

Therapeutic developers are increasingly rebuilding their workflows around AI to bring drugs to patients faster.

As climate pressure mounts, new platforms tackle delivery, regulation, trait stacking, and data bottlenecks limiting agricultural genome editing.

Non-CHO cell expression systems gain traction as faster, more flexible alternatives for biologics manufacturing.

Enzene’s New Jersey facility offers efficient, fully continuous or hybrid vat production within a modular framework.

Cas9, Transcription Activator-Like Effector Nucleases (TALENs), and Zinc-Finger nucleases (ZFNs) have demonstrated great utility, primarily for genetic knock-out applications, none have been adopted ...

I have always been a bit of a skeptic about how important AI will be for the biotechnology industry, but, given a few […] ...

Qure shares finished the regular trading week down only 9% despite the FDA’s hard-line stance and public criticism against the company’s Huntington’s disease (HD) gene therapy candidate AMT-130.

Using rodent and cellular models, the researchers showed that tanycytes take up tau from the CSF and release it into ...

The chemical exposure space is extraordinarily complex: tens of thousands of synthetic and naturally occurring compounds can enter the body.